+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Results of the treatment of hodgkin's disease in stages iii and iv with use of the doxorubicin bleomycin vinblastine dacarbazine and bleomycin doxorubicin cyclophosphamide vincristine prednisone programs



Results of the treatment of hodgkin's disease in stages iii and iv with use of the doxorubicin bleomycin vinblastine dacarbazine and bleomycin doxorubicin cyclophosphamide vincristine prednisone programs



Acta Haematologica Polonica 17(3-4): 81-90



The reported investigations were carried out in 60 patients in advanced stages of Hodgkin's disease resistant to conventional treatment (MOPP/MVPP, COPP, COPP/CVPP, ionizing radiation). The follow-up was 5 years. The patients received chemotherapy by schedules BACOP and ABVD and the selection to either group was done randomly. The proportion of complete remissions was 23.7% and their mean duration was 23.3 months. The percent of remissions obtained in groups treated according to schedules ABVD and BACOP was 35.7% and 50% respectively. No difference was observed in the duration of remission. The mean survival time in the group with complete remission was 40.1 months and in those without remission.sbd.24.2 months. Among patients with complete remission one died of another neoplasm. In the group without remission 25 patients died, 24 of them died due to progression of Hodgkin's disease. Early complications after the treatment were observed in 73% of patients. The most important among them were transient signs of marrow suppression (leucopenia in 28 cases).

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 006333391

Download citation: RISBibTeXText


Related references

Chemotherapy of hodgkin's lymphoma with alternating cycles of copp cyclophosphamide vincristine procarbazine prednisone and abvd doxorubicin bleomycin vinblastine and dacarbazine results of the hd1 and hd3 trials of the german hodgkin study group. Medical Oncology and Tumor Pharmacotherapy 6(2): 155-162, 1989

Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease. Cancer Treatment Reports 68(7-8): 947-951, 1984

Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Cancer Treatment Reports 71(12): 1203-1207, 1987

Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer 88(9): 2142-2148, 2000

Chemotherapy vs radiotherapy for remission consolidation after three double cycles of cyclophosphamide vincristine procarbazine prednisone copp and doxorubicin bleomycin vinblastine dacarbazine abvd a randomized trial in patients with stages iiib iv hodgkins lymphoma. Journal of Cancer Research & Clinical Oncology 116(Suppl. Part 1): 613, 1990

Cyclic delivery of mechlorethamine vincristine procarbazine prednisone and doxorubicin bleomycin vinblastine dacarbazine combinations in stage iv hodgkins disease rationale background studies and recent results. Cancer Treatment Reports 66(4): 881-888, 1982

Doxorubicin bleomycin vinblastine and dacarbazine salvage of mechlorethamine vincristine prednisone and procarbazine resistant advanced hodgkins disease. Cancer Treatment Reports 68(7-8): 947-952, 1984

Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer 75(7): 1706-1711, 1995

Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma. Cancer Treatment Reports 66(6): 1279-1284, 1982

Efficacy of lomustine, teniposide, doxorubicin, bleomycin and prednisone (LTABP) or adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) in the treatment of malignant lymphogranulomatosis resistant to MOPP. Polski Tygodnik Lekarski 45(21-22): 426-429, 1990

Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 22(12): 2424-2429, 2004

Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine. Cancer 51(8): 1348-1352, 1983

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104(12): 3483-3489, 2004

Phase Iii Trial of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (Chop) Versus Cisplatin, Etoposide, Bleomycin and Prednisone (CisEbp) for the Treatment of Advanced Non-Hodgkin's Lymphoma of High Grade Malignancy. Acta Oncologica 29(8): 995-999, 1990

Long-term results of patients with advanced diffuse, non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, prednisone and bleomycin (CHOP-Bleo). Oncology 40(3): 186-191, 1983